Literature DB >> 23888306

Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization.

Jongkyoung Choi1, Ji Kon Ryu, Sang Hyub Lee, Jin-Hyeok Hwang, Dong-Won Ahn, Yong-Tae Kim, Yong Bum Yoon, Chang Jin Yoon, Sung-Gwon Kang, Jin Wook Chung.   

Abstract

BACKGROUND: Nonsurgical biliary drainage is considered as a priority for obstructive jaundice associated with unresectable hepatocellular carcinoma (HCC). Successful drainage allows the patient to receive antitumor therapy, such as transarterial chemoembolization (TACE). However, only limited data are available on clinical outcomes in patients who treated biliary drainage with subsequent TACE.
OBJECTIVE: This study evaluated the clinical outcome of biliary drainage with subsequent TACE in unresectable HCC patients with obstructive jaundice.
DESIGN: This was a retrospective study. SETTING/
SUBJECTS: A total of 60 patients received endoscopic biliary drainage (ERBD) or percutaneous transhepatic biliary drainage (PTBD) in two tertiary care referral centers. MEASUREMENTS: Successful drainage and survival were measured.
RESULTS: Successful drainage was achieved in 39 (65%) patients. The median survival of 39 patients in whom successful drainage was achieved, regardless of which procedure was performed, was much longer than that of 21 patients without successful drainage (147 days versus 38 days, respectively, P<.001). In particular, the median survival was longer in 17 patients who underwent TACE after achieving successful drainage than in 22 patients who were treated conservatively after achieving successful drainage (410 days versus 77 days, respectively, P<.001). Multivariable analysis in 39 patients in the successful drainage group showed that TACE (hazard ratio 0.15; 95% confidence interval 0.05-0.45, P=.001) was an independent predictive factor of a favorable outcome.
CONCLUSIONS: Effective palliation by successful biliary drainage with subsequent TACE might prolong the survival in patients with obstructive jaundice caused by unresectable HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23888306     DOI: 10.1089/jpm.2013.0067

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  5 in total

Review 1.  Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice.

Authors:  Shuangxi Li; Xuewen He; Lei Dang; Fangyu Xu; Jin Fang; Fenqiang Li; Wenhui Wang
Journal:  Dig Dis Sci       Date:  2018-01-05       Impact factor: 3.199

2.  Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory?

Authors:  Juil Park; Hyo-Cheol Kim; Jeong-Hoon Lee; EunJu Cho; Minuk Kim; Saebeom Hur; Hwan Jun Jae; Myungsu Lee; Jin Wook Chung
Journal:  Eur Radiol       Date:  2017-11-09       Impact factor: 5.315

3.  Sloughing of biliary tumour ingrowth of hepatocellular carcinoma after chemoembolization.

Authors:  Gyoung Min Kim; Hyo-Cheol Kim; Saebeom Hur; Myungsu Lee; Hwan Jun Jae; Jin Wook Chung
Journal:  Eur Radiol       Date:  2015-09-04       Impact factor: 5.315

4.  Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice.

Authors:  Hyun Young Woo; Sung Yong Han; Jeong Heo; Dong Uk Kim; Dong Hoon Baek; So Yong Yoo; Chang Won Kim; Suk Kim; Geun Am Song; Mong Cho; Dae Hwan Kang
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

5.  Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study.

Authors:  Jin-Kai Feng; Ju-Xian Sun; Zong-Han Liu; Jing-Wen Gu; Zhen-Hua Chen; Chang Liu; Wei-Xing Guo; Jie Shi; Shu-Qun Cheng
Journal:  Cancer Manag Res       Date:  2021-04-28       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.